Biodesix press release: Wellmark BCBS of Iowa and South Dakota provides coverage for VeriStrat® Test
Heinrich Roder will speak at the 6th International Conference on Bioinformatics and Systems Biology
Biodesix raises an additional $7 million in series F financing.
Horizon Blue Cross Blue Shield (BCBS) of New Jersey has determined that the VeriStrat® proteomic test is now considered a medically necessary benefit for members with advanced NSCLC.
Biodesix to Present Data from Three Studies Indicating the Utility of Blood-Based Diagnostic Tests at AACR Annual Meeting
Biodesix to present data from three studies indicating the utility of blood-based diagnostic tests at the AACR annual meeting
With positive coverage decisions from BCBS Florida and HCSC, 200 million Americans now have insurance coverage for VeriStrat testing.
Biodesix Presentation at Molecular Med Tri-Conference: “Blood-Based Cancer Immunotherapy Diagnostics”
Dr. Heinrich Roder, will present the company’s approach and recent results for a blood test stratifying patients for immunotherapy benefit on Thursday, March 10, at Molecular Med Tri-Conference.
Norgen Biotek Corp. Announces Supply Agreement with Biodesix Enabling the First EML4-ALK Liquid Biopsy Test with Results in 72-Hours
Biodesix has selected Norgen Biotek to supply sample preparation products for its EML4-ALK blood test.
Biodesix raised $22 million through the sale of series F preferred stock and other securities.
Biodesix CEO David Brunel will present a corporate overview on Deep Phenotyping, Machine Learning to Precision Medicine at the Leerink Partners Conference